OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
A longitudinal study with four parallel cohorts with each participant followed for 2 years: two cohorts in Busia (high malaria transmission site) and two cohorts in Kampala (low malaria transmission). Each site will have a cohort of children living with HIV (CLHIV) and HIV- uninfected children and will be age-matched, enrolled in parallel, and followed for two years. All children will be enrolled without malaria infection, as determined by a negative blood smear at baseline.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 5
Maximum Age: 17
Healthy Volunteers: t
View:
• Agreement to come to the clinic for all follow-up evaluations
• Provision of informed consent and assent (as appropriate)
• Residency within approximately 30 km of the study clinic
• Negative blood smear for malaria (all sites)
• For Children and adolescents living with HIV
‣ Confirmed HIV infection
⁃ On DTG-based regimen for ≥14 days
• For HIV-uninfected children - documentation of HIV-negative status by at least 1 assay
Locations
Other Locations
Uganda
Baylor- Uganda
RECRUITING
Kampala
Infectious Disease Research Collaboration (IDRC)
RECRUITING
Kampala
Contact Information
Primary
Sunil Parikh, MD, MPH
sunil.parikh@yale.edu
1-203-737-7906
Time Frame
Start Date:2025-12-18
Estimated Completion Date:2027-12
Participants
Target number of participants:380
Treatments
Experimental: CLHIV on DTG- Kampala (Cohort 1)
CLHIV on DTG living in the low transmission malaria setting of Kampala